Cargando…
Natural compounds as inhibitors of transthyretin amyloidosis and neuroprotective agents: analysis of structural data for future drug design
Natural compounds, such as plant and fruit extracts have shown neuroprotective effect against neurodegenerative diseases. It has been reported that several natural compounds binding to transthyretin (TTR) can be useful in amyloidosis prevention. TTR is a transporter protein that under physiological...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301710/ https://www.ncbi.nlm.nih.gov/pubmed/32419519 http://dx.doi.org/10.1080/14756366.2020.1760262 |
_version_ | 1783547741832478720 |
---|---|
author | Ciccone, Lidia Tonali, Nicoló Nencetti, Susanna Orlandini, Elisabetta |
author_facet | Ciccone, Lidia Tonali, Nicoló Nencetti, Susanna Orlandini, Elisabetta |
author_sort | Ciccone, Lidia |
collection | PubMed |
description | Natural compounds, such as plant and fruit extracts have shown neuroprotective effect against neurodegenerative diseases. It has been reported that several natural compounds binding to transthyretin (TTR) can be useful in amyloidosis prevention. TTR is a transporter protein that under physiological condition carries thyroxine (T(4)) and retinol in plasma and in cerebrospinal fluid (CSF); it also has a neuroprotective role against Alzheimer’s disease (AD). However, TTR also is an amyloidogenic protein responsible for familial amyloid polyneuropathy (FAP) and familial amyloid cardiomyopathy (FAC). The TTR amyloidogenic potential is speeded up by several point mutations. One therapeutic strategy against TTR amyloidosis is the stabilisation of the native tetramer by natural compounds and small molecules. In this review, we examine the natural products that, starting from 2012 to present, have been studied as a stabiliser of TTR tetramer. In particular, we discussed the chemical and structural features which will be helpful for future drug design of new TTR stabilisers. |
format | Online Article Text |
id | pubmed-7301710 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-73017102020-06-25 Natural compounds as inhibitors of transthyretin amyloidosis and neuroprotective agents: analysis of structural data for future drug design Ciccone, Lidia Tonali, Nicoló Nencetti, Susanna Orlandini, Elisabetta J Enzyme Inhib Med Chem Review Article Natural compounds, such as plant and fruit extracts have shown neuroprotective effect against neurodegenerative diseases. It has been reported that several natural compounds binding to transthyretin (TTR) can be useful in amyloidosis prevention. TTR is a transporter protein that under physiological condition carries thyroxine (T(4)) and retinol in plasma and in cerebrospinal fluid (CSF); it also has a neuroprotective role against Alzheimer’s disease (AD). However, TTR also is an amyloidogenic protein responsible for familial amyloid polyneuropathy (FAP) and familial amyloid cardiomyopathy (FAC). The TTR amyloidogenic potential is speeded up by several point mutations. One therapeutic strategy against TTR amyloidosis is the stabilisation of the native tetramer by natural compounds and small molecules. In this review, we examine the natural products that, starting from 2012 to present, have been studied as a stabiliser of TTR tetramer. In particular, we discussed the chemical and structural features which will be helpful for future drug design of new TTR stabilisers. Taylor & Francis 2020-05-18 /pmc/articles/PMC7301710/ /pubmed/32419519 http://dx.doi.org/10.1080/14756366.2020.1760262 Text en © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Ciccone, Lidia Tonali, Nicoló Nencetti, Susanna Orlandini, Elisabetta Natural compounds as inhibitors of transthyretin amyloidosis and neuroprotective agents: analysis of structural data for future drug design |
title | Natural compounds as inhibitors of transthyretin amyloidosis and neuroprotective agents: analysis of structural data for future drug design |
title_full | Natural compounds as inhibitors of transthyretin amyloidosis and neuroprotective agents: analysis of structural data for future drug design |
title_fullStr | Natural compounds as inhibitors of transthyretin amyloidosis and neuroprotective agents: analysis of structural data for future drug design |
title_full_unstemmed | Natural compounds as inhibitors of transthyretin amyloidosis and neuroprotective agents: analysis of structural data for future drug design |
title_short | Natural compounds as inhibitors of transthyretin amyloidosis and neuroprotective agents: analysis of structural data for future drug design |
title_sort | natural compounds as inhibitors of transthyretin amyloidosis and neuroprotective agents: analysis of structural data for future drug design |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301710/ https://www.ncbi.nlm.nih.gov/pubmed/32419519 http://dx.doi.org/10.1080/14756366.2020.1760262 |
work_keys_str_mv | AT cicconelidia naturalcompoundsasinhibitorsoftransthyretinamyloidosisandneuroprotectiveagentsanalysisofstructuraldataforfuturedrugdesign AT tonalinicolo naturalcompoundsasinhibitorsoftransthyretinamyloidosisandneuroprotectiveagentsanalysisofstructuraldataforfuturedrugdesign AT nencettisusanna naturalcompoundsasinhibitorsoftransthyretinamyloidosisandneuroprotectiveagentsanalysisofstructuraldataforfuturedrugdesign AT orlandinielisabetta naturalcompoundsasinhibitorsoftransthyretinamyloidosisandneuroprotectiveagentsanalysisofstructuraldataforfuturedrugdesign |